JP5681276B2 - 肺高血圧症のための治療 - Google Patents

肺高血圧症のための治療 Download PDF

Info

Publication number
JP5681276B2
JP5681276B2 JP2013500129A JP2013500129A JP5681276B2 JP 5681276 B2 JP5681276 B2 JP 5681276B2 JP 2013500129 A JP2013500129 A JP 2013500129A JP 2013500129 A JP2013500129 A JP 2013500129A JP 5681276 B2 JP5681276 B2 JP 5681276B2
Authority
JP
Japan
Prior art keywords
inhalation
treprostinil
oral
therapeutic agent
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013500129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522303A5 (enExample
JP2013522303A (ja
Inventor
ロスブラット，マーティン，エー．
ルビン，ルイス，ジェイ．
Original Assignee
ユナイテッド セラピューティクス コーポレイション
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレイション, ユナイテッド セラピューティクス コーポレイション filed Critical ユナイテッド セラピューティクス コーポレイション
Publication of JP2013522303A publication Critical patent/JP2013522303A/ja
Publication of JP2013522303A5 publication Critical patent/JP2013522303A5/ja
Application granted granted Critical
Publication of JP5681276B2 publication Critical patent/JP5681276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2013500129A 2010-03-15 2011-03-14 肺高血圧症のための治療 Active JP5681276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28265910P 2010-03-15 2010-03-15
US61/282,659 2010-03-15
PCT/US2011/028390 WO2011115922A1 (en) 2010-03-15 2011-03-14 Treatment for pulmonary hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015002312A Division JP2015129129A (ja) 2010-03-15 2015-01-08 肺高血圧症のための治療

Publications (3)

Publication Number Publication Date
JP2013522303A JP2013522303A (ja) 2013-06-13
JP2013522303A5 JP2013522303A5 (enExample) 2014-05-01
JP5681276B2 true JP5681276B2 (ja) 2015-03-04

Family

ID=43858371

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013500129A Active JP5681276B2 (ja) 2010-03-15 2011-03-14 肺高血圧症のための治療
JP2015002312A Pending JP2015129129A (ja) 2010-03-15 2015-01-08 肺高血圧症のための治療
JP2016052406A Withdrawn JP2016153413A (ja) 2010-03-15 2016-03-16 肺高血圧症のための治療
JP2018089769A Pending JP2018135383A (ja) 2010-03-15 2018-05-08 肺高血圧症のための治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015002312A Pending JP2015129129A (ja) 2010-03-15 2015-01-08 肺高血圧症のための治療
JP2016052406A Withdrawn JP2016153413A (ja) 2010-03-15 2016-03-16 肺高血圧症のための治療
JP2018089769A Pending JP2018135383A (ja) 2010-03-15 2018-05-08 肺高血圧症のための治療

Country Status (8)

Country Link
US (2) US8609728B2 (enExample)
EP (2) EP3108888B1 (enExample)
JP (4) JP5681276B2 (enExample)
KR (3) KR101508047B1 (enExample)
CN (1) CN102883722B (enExample)
CA (2) CA2892104C (enExample)
ES (2) ES2790859T3 (enExample)
WO (1) WO2011115922A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
US8481782B2 (en) 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production
KR101454571B1 (ko) 2011-03-02 2014-10-23 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐 생산을 위한 중간체 합성
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
KR20150128903A (ko) 2013-03-15 2015-11-18 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 염
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CN116531490A (zh) * 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
EP4620525A3 (en) * 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
HU231296B1 (hu) * 2018-03-09 2022-09-28 Chinoin Zrt Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására
EP3853200B1 (en) 2018-09-18 2024-01-24 Eli Lilly and Company Erbumine salt of treprostinil
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
WO2021041320A1 (en) 2019-08-23 2021-03-04 United Therapeutics Corporation Treprostinil prodrugs
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
KR20250133451A (ko) 2020-12-14 2025-09-05 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
US20230263807A1 (en) 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
KR20250002687A (ko) 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제
AU2024208919A1 (en) 2023-01-19 2025-07-17 United Therapeutics Corporation Treprostinil analogs

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
KR100638684B1 (ko) 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
ES2670872T3 (es) 2003-05-22 2018-06-01 United Therapeutics Corporation Polimorfo de una sal de dietanolamina de treprostinil
US8765813B2 (en) 2003-12-16 2014-07-01 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
JP4906514B2 (ja) 2003-12-16 2012-03-28 ユナイテッド セラピューティクス コーポレイション 腎臓機能改善のためのトレプロスチニルの用途
CA2562614C (en) 2004-04-12 2013-09-17 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US20080280986A1 (en) 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
EP2711024B1 (en) 2007-09-07 2019-03-06 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
KR20110010753A (ko) 2008-05-08 2011-02-07 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐 일수화물
US20120177693A1 (en) 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
EP2427054A4 (en) 2009-05-07 2014-01-15 United Therapeutics Corp SOLID COMPOSITIONS BASED ON PROSTACYCLINE ANALOGS
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
US20120010159A1 (en) 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil

Also Published As

Publication number Publication date
WO2011115922A1 (en) 2011-09-22
JP2015129129A (ja) 2015-07-16
CA2892104C (en) 2016-08-30
EP3108888B1 (en) 2020-02-12
KR20160132501A (ko) 2016-11-18
CA2791081A1 (en) 2011-09-22
CA2892104A1 (en) 2011-09-22
CA2791081C (en) 2015-08-25
US8609728B2 (en) 2013-12-17
CN102883722B (zh) 2014-11-05
EP3108888A1 (en) 2016-12-28
JP2016153413A (ja) 2016-08-25
JP2018135383A (ja) 2018-08-30
ES2611187T3 (es) 2017-05-05
EP2547341B1 (en) 2016-09-14
KR20130038835A (ko) 2013-04-18
JP2013522303A (ja) 2013-06-13
CN102883722A (zh) 2013-01-16
EP2547341A1 (en) 2013-01-23
KR20150027846A (ko) 2015-03-12
US20110224236A1 (en) 2011-09-15
US8969409B2 (en) 2015-03-03
US20130253049A1 (en) 2013-09-26
ES2790859T3 (es) 2020-10-29
KR101508047B1 (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
JP2018135383A (ja) 肺高血圧症のための治療
CN1196479C (zh) 吸入形式的苯并茚前列腺素制剂的用途
US20220008436A1 (en) Treprostinil administration by inhalation
US20050101608A1 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US8324247B2 (en) Method for treating pulmonary arterial hypertension
RS64884B1 (sr) Formulacije ciklosporina za upotrebu u prevenciji ili lečenju hroničnog odbacivanja plućnog transplantata
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
JP7369523B2 (ja) 中等度～重度のインフルエンザの処置
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
KR20190030805A (ko) 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
EP1354588A1 (en) Method for delivering benzindene prostaglandind by inhalation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140311

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140311

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150108

R150 Certificate of patent or registration of utility model

Ref document number: 5681276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250